Shanghai Weizhi Zhuo Biotechnology

Shanghai Weizhi Zhuo Biotechnology is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative small molecule drugs for challenging "undruggable" targets. The company focuses primarily on oncology, with a strong emphasis on the RAS signaling pathway and other key oncogenic drivers. Its lead program, WZZ-001, is a highly selective KRAS G12D inhibitor that has entered Phase 1 clinical trials for patients with advanced solid tumors. By integrating structural biology, computational chemistry, and advanced screening technologies, Weizhi Zhuo aims to deliver breakthrough therapies for cancer patients worldwide. The company is backed by prominent venture capital firms and led by a team of experienced drug discovery professionals.